It could be found that the number of MS prevalence cases in each group was 3, 14, 17, and 24, accounting for 9.4%, 45.2%, 54.8%, and 77.4%, respectively, and with the elevation of GDF15 levels, the MS prevalence gradually increased with increasing GDF15 levels (p < 0.05). The gene discussed is GDF15; the disease is myeloid sarcoma.